Moreover, YVAD treatment significantly preserved VE-cadherin levels with decreased levels of vimentin and α-SMA in vascular endothelial cells after bleomycin-induced pulmonary fibrosis (Figure 3D,E). This evidence concerns the gene CDH5 and pulmonary fibrosis.